Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients | Zendy

Bezawit A. Woldemeskel | Zendy; Caroline C. Garliss | Zendy; Tihitina Y. Aytenfisu | Zendy; Trevor S. Johnston | Zendy; Andrea L. Cox | Zendy; Andrew H. Karaba | Zendy; Joel N. Blankson | Zendy

Open Access

Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients

Author(s) -

Bezawit A. Woldemeskel,

Caroline C. Garliss,

Tihitina Y. Aytenfisu,

Trevor S. Johnston,

Andrea L. Cox,

Andrew H. Karaba,

Joel N. Blankson

Publication year - 2022

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciac305

Subject(s) - antibody , coronavirus , virology , medicine , messenger rna , rna , respiratory system , covid-19 , immunology , disease , gene , biology , infectious disease (medical specialty) , pathology , genetics

We compared antibody and T cell responses against the SARS-CoV-2 vaccine strain spike protein to responses against the Omicron variant in 15 mRNA vaccine recipients. While these individuals had significantly lower levels of antibodies that inhibited Omicron spike protein binding to ACE2, there was no difference in T cell responses.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research